Tanaka, Naoki

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation

Liver Disease Diagnosis and TreatmentGut microbiota and health

Cited by 693

Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology

Liver Disease Diagnosis and TreatmentFatty Acid Research and Health

Cited by 248

Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice

Tanaka, N., Zhang, X., Sugiyama, E., Kono, H., Horiuchi, A., Nakajima, T., Kanbe, H., Tanaka, E., Gonzalez, F. J., & Aoyama, T. (2010) · Biochemical Pharmacology

Fatty Acid Research and HealthLiver Disease Diagnosis and Treatment

Cited by 78

Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-activated receptor alpha

Sugiyama, E., Ishikawa, Y., Li, Y., Kagai, T., Nobayashi, M., Tanaka, N., Kamijo, Y., Yokoyama, S., Hara, A., & Aoyama, T. (2008) · Life Sciences

Fatty Acid Research and HealthCholesterol and Lipid Metabolism

Cited by 43

Modulation of Ammonium Perfluorooctanoate-Induced Hepatic Damage by Genetically Different PPARα in Mice

Nakagawa, T., Ramdhan, D. H., Tanaka, N., Naito, H., Tamada, H., Ito, Y., Li, Y., Hayashi, Y., Yamagishi, N., Yanagiba, Y., et al. (2012) · Archives of Toxicology

Per- and polyfluoroalkyl substances researchPeroxisome Proliferator-Activated Receptors

Cited by 33